Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZLAB · against 367 other Healthcare companies of similar size
Ranked #270 of 368 · scores higher than 5% of peers
Bars: peers in each 10-point band of the valuation score99 peers with a valuation score of 0–9, including ZLAB · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ZLAB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 358 reported | -7.7% | 2.2% | 17% | 30% | |
| EBITDA yieldHigher is better · 366 reported | -11.8% | 4.5% | 10% | 50% | |
| Free cash flow yieldHigher is better · 181 reported | -6.6% | -0.2% | 23% | 20% | |
| Book yieldHigher is better · 358 reported | 24.6% | 32.8% | 36% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 270 | 2.0B USD | 8 | 29 | |
| 270 | 3.7B USD | 8 | 28 | |
| 270 | 2.3B USD | 8 | 27 | |
| 270 | 1.8B USD | 8 | 23 | |
| 270 | 2.5B USD | 8 | 31 | |
| 270 | 2.2B USD | 8 | 20 | |
| 349 | 18.5B CNY (≈$2.6B) | 7 | 37 | |
| 350 | 9.3B CNY (≈$1.3B) | 0 | 32 | |
| 350 | 9.6B CNY (≈$1.3B) | 0 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score